US pharmaceutical “Pfizer” announced an investment of 280 million pesos ($15 million USD) this year in clinical research for Mexico.
Alfredo Chi, medical director of the company in Mexico, told Forbes magazine that the company has great confidence in researchers and centers in the country, so they have decided to collaborate with Mexican specialists, health institutes and academic institutions such as UNAM.
US pharmaceutical “Pfizer” announced an investment of 280 million pesos this year in clinical research for Mexico.
Pfizer currently has 60 research protocols involving more than 800 patients, and if the support from government agencies continues, Mexico would be positioned among the top 10 countries for this activity in the world.
The company is focusing mostly in cancer treatments, as well as chronic and degenerative diseases such as rheumatoid arthritis, cardiovascular problems, and methods to combat discomfort associated with pain and inflammation.
Imagen Original: “New York City – Pfizer World Headquarters” por Norbert Nagel, Mörfelden-Walldorf, Germany bajo licencia CC BY-SA 3.0, vía Wikimedia Commons.
The executive added that Pfizer devotes great energy to bring and do research processes, to offer products and medications that are safe and effective, in order to prolong the life of the population.
Globally, the US company allocates between 17% and 18% of its annual total investment – about $7 billion USD – in research processes that are carried out in the more than 120 countries where it operates.
Currently the company is preparing to launch a new drug for the treatment of metastatic breast cancer.
Source: Mexico News Network
